Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 1.00 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.58 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | PRKCI | P41743 | 1/20 | 0.52 |
| ▸ | MET | P08581 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.49 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.49 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.49 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.47 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.47 |
| ▸ | CDC7 | O00311 | 3/20 | 0.46 |
| ▸ | CDK2 | P24941 | 2/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.46 |
| ▸ | PIM1 | P11309 | 2/20 | 0.46 |
| ▸ | PRKACA | P17612 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29655460 | 1.00 | AXL (1.00) | AXLGPR84LRRK2KMT2APRKCI | |
| SCHEMBL5618155 | 0.78 | TGFBR1 (0.71) | AXLGPR84LRRK2KMT2ATGFBR1 | |
| SCHEMBL20846162 | 0.78 | AXL (0.64) | AXLGPR84TGFBR1PDPK1IKBKE | |
| SCHEMBL2111969 | 0.75 | AXL (0.60) | AXLGPR84LRRK2KMT2AMET | |
| SCHEMBL12605500 | 0.75 | AXL (0.60) | AXLGPR84LRRK2KMT2AMET | |
| SCHEMBL5802606 | 0.75 | AXL (0.60) | AXLGPR84LRRK2KMT2AMET | |
| SCHEMBL412615 | 0.75 | AXL (0.60) | AXLGPR84LRRK2KMT2AMET | |
| SCHEMBL31097189 | 0.75 | AXL (0.60) | AXLGPR84LRRK2KMT2APRKCI | |
| SCHEMBL368676 | 0.75 | AXL (0.60) | AXLGPR84LRRK2KMT2AMET | |
| SCHEMBL12188 | 0.75 | AXL (0.60) | AXLGPR84LRRK2KMT2AMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 388 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150284388-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | VERTEX PHARMACEUTICALS INCORPORATED | 2015-10-08 | — | — | US | claimed |
| US-20150099884-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | VERTEX PHARMACEUTICALS INCORPORATED | 2015-04-09 | — | — | US | claimed |
| US-20140309421-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | VERTEX PHARMACEUTICALS INCORPORATED | 2014-10-16 | — | — | US | claimed |
| EP-2729465-A2 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | Vertex Pharmaceuticals Incorporated (US) | 2014-05-14 | — | — | EP | claimed |
| US-8513414-B2 | Processes and intermediates for producing azaindoles | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-20 | — | — | US | claimed |
| US-20130102782-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-25 | — | — | US | claimed |
| WO-2013006634-A9 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-21 | — | — | WO | claimed |
| WO-2013006634-A2 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-10 | — | — | WO | claimed |
| US-20260116903-A1 | AROMATIC HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | RECURSION PHARMACEUTICALS INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4720058-A2 | BIFUNCTIONAL DEGRADERS AND USES THEREOF | Casma Therapeutics, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12540149-B2 | Aromatic heterocyclic compound, pharmaceutical composition, and use thereof | RECURSION PHARMACEUTICALS, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-20250326772-A1 | MRGPRX2 ANTAGONISTS, PHARMACEUTICAL COMPOSITION INCLUDING MRGPRX2 ANTAGONIST, AND METHOD OF TREATING MRGPRX2-MEDIATED DISEASE OR DISORDER | KYORIN SEIYAKU KK (JP) | 2025-10-23 | — | — | US | disclosed |
| US-20250326773-A1 | MRGPRX2 ANTAGONISTS, PHARMACEUTICAL COMPOSITION INCLUDING MRGPRX2 ANTAGONIST, AND METHOD OF TREATING MRGPRX2-MEDIATED DISEASE OR DISORDER | KYORIN SEIYAKU KK (JP) | 2025-10-23 | — | — | US | disclosed |
| US-12448368-B2 | Indole compounds as androgen receptor modulators | NIDO BIOSCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20060100218-A1 | Phosphodiesterase 4; asthma, chronic obstructive pulmonary disease, Alzheimer's disease, diffuse large-cell B cell lymphoma, and chronic lymphocytic leukemia; 8-[3-(3,4-dimethoxy-phenyl)-pyrrolo[2,3-b]pyridine-1-sulfonyl]-quinoline | PLEXXIKON, INC. | 2006-05-11 | — | — | US | disclosed |
| US-20060084674-A1 | Azaindole thiazolinones | CHEN SHAOQING | 2006-04-20 | — | — | US | disclosed |
| WO-2006040049-A1 | NOVEL AZAINDOLE THIAZOLINONES AS ANTI-CANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006026754-A9 | BICYCLIC HETEROARYL PDE4B INHIBITORS | PLEXXIKON INC (US) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006026754-A2 | BICYCLIC HETEROARYL PDE4B INHIBITORS | PLEXXIKON, INC. (US) | 2006-03-09 | — | — | WO | disclosed |
| WO-2005095400-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100218-A1 | Phosphodiesterase 4; asthma, chronic obstructive pulmonary disease, Alzheimer's disease, diffuse large-cell B cell lymphoma, and chronic lymphocytic leukemia; 8-[3-(3,4-dimethoxy-phenyl)-pyrrolo[2,3-b]pyridine-1-sulfonyl]-quinoline | PDE4B, PDE4A, PDE4C | AXL 4409/4885GPR84 2695/4885LRRK2 1803/4885 |
| US-20150099884-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | JAK2, JAK3, JAK1 | AXL 1344/4885GPR84 3870/4885LRRK2 1706/4885 |
| US-20140309421-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | JAK2, JAK3, JAK1 | AXL 1344/4885GPR84 3870/4885LRRK2 1706/4885 |
| US-20250326772-A1 | MRGPRX2 ANTAGONISTS, PHARMACEUTICAL COMPOSITION INCLUDING MRGPRX2 ANTAGONIST, AND METHOD OF TREATING MRGPRX2-MEDIATED DISEASE OR DISORDER | MRGPRX2, MRGPRX1, MRGPRX4 | AXL 4764/4885GPR84 545/4885LRRK2 1065/4885 |
| US-12540149-B2 | Aromatic heterocyclic compound, pharmaceutical composition, and use thereof | CDK7, CDK17, CDK1 | AXL 1612/4885GPR84 4000/4885LRRK2 1133/4885 |
| US-20250326773-A1 | MRGPRX2 ANTAGONISTS, PHARMACEUTICAL COMPOSITION INCLUDING MRGPRX2 ANTAGONIST, AND METHOD OF TREATING MRGPRX2-MEDIATED DISEASE OR DISORDER | MRGPRX2, MRGPRX1, MRGPRX4 | AXL 4764/4885GPR84 545/4885LRRK2 1065/4885 |
| US-20260116903-A1 | AROMATIC HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | CDK7, CDK8, CDK6 | AXL 1089/4885GPR84 4087/4885LRRK2 1328/4885 |
| US-20130102782-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | JAK2, JAK3, JAK1 | AXL 1344/4885GPR84 3870/4885LRRK2 1706/4885 |
| US-12448368-B2 | Indole compounds as androgen receptor modulators | AR, FSHR, ADRB3 | AXL 3932/4885GPR84 181/4885LRRK2 199/4885 |
| US-20060084674-A1 | Azaindole thiazolinones | CDK1, CDK2, CDK12 | AXL 1304/4885GPR84 2985/4885LRRK2 1803/4885 |
| US-20150284388-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING AZAINDOLES | JAK2, JAK3, JAK1 | AXL 1344/4885GPR84 3870/4885LRRK2 1706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.